Truist Securities Maintains Hold on Inari Medical, Lowers Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a Hold rating on Inari Medical (NARI) and lowers the price target from $61 to $52.
March 22, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Truist Securities maintains a Hold rating on Inari Medical and lowers the price target from $61 to $52.
The reduction in price target by Truist Securities suggests a less optimistic outlook on Inari Medical's stock performance in the short term. This adjustment could lead to a negative perception among investors, potentially causing a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100